Document is current
Any future updates will be listed below
-
Authors
Huneke, Nathan T. M. https://orcid.org/0000-0001-5981-6707
Amin, Jay https://orcid.org/0000-0003-3792-0428
Baldwin, David S.
Bellato, Alessio
Brandt, Valerie https://orcid.org/0000-0002-3208-2659
Chamberlain, Samuel R.
Correll, Christoph U. https://orcid.org/0000-0002-7254-5646
Eudave, Luis
Garner, Matthew
Gosling, Corentin J.
Hill, Catherine M.
Hou, Ruihua
Howes, Oliver D. https://orcid.org/0000-0002-2928-1972
Ioannidis, Konstantinos
Köhler-Forsberg, Ole
Marzulli, Lucia
Reed, Claire https://orcid.org/0000-0003-1385-4729
Sinclair, Julia M. A.
Singh, Satneet
Solmi, Marco https://orcid.org/0000-0003-4877-7233
Cortese, Samuele https://orcid.org/0000-0001-5877-8075
- License Information
-
More Information
Article History
Received: 1 February 2024
Revised: 17 June 2024
Accepted: 19 June 2024
First Online: 24 June 2024
Competing interests
: DSB is President of the British Association for Psychopharmacology, Editor of <i>the Human Psychopharmacology</i> journal (for which he receives an editor’s honorarium), and has received royalties from UpToDate. CMH has acted on an expert advisory board for Neurim Pharmaceuticals. ODH is a part-time employee and stockholder of Lundbeck A/s. He has received investigator-initiated research funding from and/or participated in advisory/speaker meetings organized by Angellini, Autifony, Biogen, Boehringer-Ingelheim, Eli Lilly, Heptares, Global Medical Education, Invicro, Jansenn, Lundbeck, Neurocrine, Otsuka, Sunovion, Recordati, Roche and Viatris/Mylan. ODH has a patent for the use of dopaminergic imaging. All other authors declare no competing interests. MS has received honoraria/has been a consultant for Angelini, Lundbeck, and Otsuka. SCo has received honoraria from non-profit associations (BAP, ACAMH, CADDRA) for educational activities and an honorarium from Medice. KI has received honoraria from Elsevier for editorial work. SRC receives honoraria from Elsevier for associate editor roles at comprehensive psychiatry and NBR journals. CUC has been a consultant and/or advisor to or has received honoraria from: AbbVie, Acadia, Adock Ingram, Alkermes, Allergan, Angelini, Aristo, Biogen, Boehringer-Ingelheim, Bristol-Meyers Squibb, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Denovo, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Jamjoom Pharma, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Merck, Mindpax, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Neurelis, Newron, Noven, Novo Nordisk, Otsuka, Pharmabrain, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Sage, Seqirus, SK Life Science, Sumitomo Pharma America, Sunovion, Sun Pharma, Supernus, Takeda, Teva, Tolmar, Vertex, and Viatris. He provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Compass Pathways, Denovo, Lundbeck, Relmada, Reviva, Rovi, Supernus, and Teva. He has received grant support from Janssen and Takeda. He received royalties from UpToDate and is also a stock option holder of Cardio Diagnostics, Kuleon Biosciences, LB Pharma, Mindpax, and Quantic.
